Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dobesilate→

Dobesilate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
20123-80-2
Molecular formula
C6H6O5S
Molecular weight
190.18 g/mol
Drug class
Vasoprotective agentcalcium dobesilate active anion
Mechanism of action
Reduces capillary permeability and fragility and may improve microvascular blood rheology and endothelial function. Its pharmacology is associated with modulation of vascular basement-membrane and inflammatory processes; the full molecular mechanism is not completely defined. Calcium is a counter-ion in calcium dobesilate.
Indications / reported uses
  • Symptomatic treatment of chronic venous insufficiency and associated lower-limb symptoms in countries where authorised
  • Some country-specific product information includes diabetic retinopathy or haemorrhoidal symptoms; verify the current local label before assigning these uses

Sources: PubMed — Calcium dobesilate pharmacology and clinical use · EMA medicines search — dobesilate · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Vasoprotective agent; calcium dobesilate active anion

Mechanism of action

Reduces capillary permeability and fragility and may improve microvascular blood rheology and endothelial function. Its pharmacology is associated with modulation of vascular basement-membrane and inflammatory processes; the full molecular mechanism is not completely defined. Calcium is a counter-ion in calcium dobesilate.

General use cases

  • Symptomatic treatment of chronic venous insufficiency and associated lower-limb symptoms in countries where authorised
  • Some country-specific product information includes diabetic retinopathy or haemorrhoidal symptoms; verify the current local label before assigning these uses

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Dobesilate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dobesilate Permitted Daily Exposure (PDE) report (the Dobesilate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dobesilate Occupational Exposure Limit (OEL) report (the Dobesilate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.